Literature DB >> 17027750

Antidepressants enhance the antinociceptive effects of carbamazepine in the acetic acid-induced writhing test in mice.

Mieko Aoki1, Minoru Tsuji, Hiroshi Takeda, Yoichiro Harada, Jun Nohara, Teruhiko Matsumiya, Hiroshige Chiba.   

Abstract

Some antidepressants, as well as antiepileptics, are effective for treating pain of varying etiology. The present study was designed to characterize the antinociceptive effects of imipramine, a tricyclic antidepressant, fluvoxamine, a selective serotonin reuptake inhibitor, milnacipran, a serotonin noradrenaline reuptake inhibitor, and carbamazepine, an antiepileptic drug, using the acetic acid-induced writhing test in mice. Imipramine (1.25-10 mg/kg, i.p.), fluvoxamine (5-40 mg/kg, i.p.) and milnacipran (2.5-20 mg/kg, i.p.) all dose-dependently and significantly reduced the number of writhes induced by the injection of acetic acid (0.8% (v/v)), although the maximal effect of milnacipran was weaker than those of imipramine and fluvoxamine. Similarly, carbamazepine (5-20 mg/kg, i.p.) also showed a dose-dependent and significant antinociceptive effect. In combination studies, the co-administration of a sub-effective dose of carbamazepine (5 mg/kg, i.p.) with imipramine (1.25 and 2.5 mg/kg, i.p.), fluvoxamine (10 mg/kg, i.p.) or milnacipran (1.25 and 2.5 mg/kg, i.p.) significantly reduced the number of writhes. Additionally, the hole-board test revealed that the medications with significant antinociceptive effects barely produced changes in motor activity that could possibly affect writhing behavior. Thus, the present study demonstrated that the antinociceptive effect of carbamazepine is enhanced by combination with imipramine, fluvoxamine and milnacipran. Therefore, the combined therapy using antidepressants and carbamazepine may be useful clinically for the control of pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17027750     DOI: 10.1016/j.ejphar.2006.08.049

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats.

Authors:  Marisa B Rosenberg; F Ivy Carroll; S Stevens Negus
Journal:  J Pain       Date:  2013-01-16       Impact factor: 5.820

2.  Evaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor.

Authors:  Ting-Ting Zhang; Rui Xue; Lei Zhu; Juan Li; Qiong-Yin Fan; Bo-Hua Zhong; Yun-Feng Li; Cai-Ying Ye; You-Zhi Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-07-18       Impact factor: 6.150

3.  Evaluation of Anti-inflammatory and Analgesic Activity of the Extract and Fractions of Astragalus hamosus in Animal Models.

Authors:  Asie Shojaii; Majid Motaghinejad; Sima Norouzi; Manijeh Motevalian
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

4.  LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice.

Authors:  Juliane Cabral Silva; Raimundo Gonçalves de Oliveira Júnior; Mariana Gama E Silva; Érica Martins de Lavor; Juliana Mikaelly Dias Soares; Sarah Raquel Gomes de Lima-Saraiva; Tâmara Coimbra Diniz; Rosemairy Luciane Mendes; Edilson Beserra de Alencar Filho; Eliezer Jesus de Lacerda Barreiro; Lídia Moreira Lima; Jackson Roberto Guedes da Silva Almeida
Journal:  PLoS One       Date:  2018-07-30       Impact factor: 3.240

5.  Antinociceptive and anti-inflammatory effects of hydrazone derivatives and their possible mechanism of action in mice.

Authors:  Maria Alice Miranda Bezerra Medeiros; Mariana Gama E Silva; Jackson de Menezes Barbosa; Érica Martins de Lavor; Tiago Feitosa Ribeiro; Cícero André Ferreira Macedo; Luiz Antonio Miranda de Souza Duarte-Filho; Thiala Alves Feitosa; Jussara de Jesus Silva; Harold Hilarion Fokoue; Cleônia Roberta Melo Araújo; Arlan de Assis Gonsalves; Luciano Augusto de Araújo Ribeiro; Jackson Roberto Guedes da Silva Almeida
Journal:  PLoS One       Date:  2021-11-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.